137 related articles for article (PubMed ID: 25173576)
1. Maintenance of virologic efficacy and decrease in levels of β2-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI-sparing dual therapy.
Romero-Sánchez MC; Alvarez-Ríos AI; Bernal-Morell E; Genebat M; Vera F; Benhnia MR; Bravo-Urbieta J; Galera-Peñaranda C; de Pablo-Bernal RS; Abad-Carrillo MA; Leal M; Ruiz-Mateos E;
Antiviral Res; 2014 Nov; 111():26-32. PubMed ID: 25173576
[TBL] [Abstract][Full Text] [Related]
2. Improvement of endothelial function after switching previously treated HIV-infected patients to an NRTI-sparing bitherapy with maraviroc.
Bernal E; Verdú JM; Vera F; Martinez O; Bravo J; Galera C; Muñoz A; Garcia E; Serrano J; Perez A; Vera C; Marín I; Cano A
J Int AIDS Soc; 2014; 17(4 Suppl 3):19726. PubMed ID: 25397472
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.
Macías J; Recio E; Márquez M; García C; Jiménez P; Merino D; Muñoz L; Pasquau J; Ojeda G; Bancalero P; Chueca N; Pineda JA
HIV Med; 2014 Aug; 15(7):417-24. PubMed ID: 24580801
[TBL] [Abstract][Full Text] [Related]
4. Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.
Waters L; Jackson A; Else L; Rockwood N; Newell S; Back D; Nelson M; Gazzard B; Boffito M
Antivir Ther; 2015; 20(2):157-63. PubMed ID: 24963558
[TBL] [Abstract][Full Text] [Related]
5. Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load.
Vitiello P; Brudney D; MacCartney M; Garcia A; Smith C; Marshall N; Johnson M; Geretti AM
Intervirology; 2012; 55(2):172-8. PubMed ID: 22286889
[TBL] [Abstract][Full Text] [Related]
6. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
7. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Reliquet V; Chirouze C; Allavena C; Muret P; Peytavin G; André-Garnier E; Bettinger D; Ferré V; Hoen B; Raffi F
Antivir Ther; 2014; 19(1):117-23. PubMed ID: 24145365
[TBL] [Abstract][Full Text] [Related]
8. Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience.
Nozza S; Galli L; Visco F; Soria A; Canducci F; Salpietro S; Gianotti N; Bigoloni A; Torre LD; Tambussi G; Lazzarin A; Castagna A
AIDS; 2010 Mar; 24(6):924-8. PubMed ID: 20154578
[TBL] [Abstract][Full Text] [Related]
9. Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens.
Gonzalez-Serna A; Ferrando-Martinez S; Tarancon-Diez L; De Pablo-Bernal RS; Dominguez-Molina B; Jiménez JL; Muñoz-Fernández MÁ; Leal M; Ruiz-Mateos E
J Transl Med; 2017 Dec; 15(1):259. PubMed ID: 29262860
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.
Imaz A; Llibre JM; Mora M; Mateo G; Camacho A; Blanco JR; Curran A; Santos JR; Caballero E; Bravo I; Gayá F; Domingo P; Rivero A; Falcó V; Clotet B; Ribera E
J Antimicrob Chemother; 2011 Feb; 66(2):358-62. PubMed ID: 21172789
[TBL] [Abstract][Full Text] [Related]
11. Effect of maraviroc on HIV disease progression-related biomarkers.
Romero-Sánchez MC; Machmach K; Gonzalez-Serna A; Genebat M; Pulido I; García-García M; Alvarez-Ríos AI; Ferrando-Martinez S; Ruiz-Mateos E; Leal M
Antimicrob Agents Chemother; 2012 Nov; 56(11):5858-64. PubMed ID: 22948867
[TBL] [Abstract][Full Text] [Related]
12. Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine.
Nozza S; Galli L; Bigoloni A; Gianotti N; Spagnuolo V; Carbone A; Chiappetta S; Ripa M; Tambussi G; Lazzarin A; Castagna A
New Microbiol; 2014 Apr; 37(2):145-51. PubMed ID: 24858641
[TBL] [Abstract][Full Text] [Related]
13. Potential anti-inflammatory effects of maraviroc in HIV-positive patients: a pilot study of inflammation, endothelial dysfunction, and coagulation markers.
Francisci D; Falcinelli E; Baroncelli S; Petito E; Cecchini E; Weimer LE; Floridia M; Gresele P; Baldelli F
Scand J Infect Dis; 2014 Jun; 46(6):466-70. PubMed ID: 24738757
[TBL] [Abstract][Full Text] [Related]
14. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
[TBL] [Abstract][Full Text] [Related]
15. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
[TBL] [Abstract][Full Text] [Related]
16. T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity.
Pulido I; Machmach K; Romero-Sánchez MC; Genebat M; Mendez-Lagares G; Ruiz-Mateos E; Leal M
J Infect; 2012 Apr; 64(4):417-23. PubMed ID: 22227467
[TBL] [Abstract][Full Text] [Related]
17. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
18. Enfuvirtide in HIV-1-infected individuals changing therapy to a nucleoside reverse transcriptase inhibitor sparing regimen: the ALLIANCE Study.
Dwyer DE; Workman C; Hales G; Amin J; Cooper D; Miller J;
Antivir Ther; 2006; 11(4):409-19. PubMed ID: 16856614
[TBL] [Abstract][Full Text] [Related]
19. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
Puertas MC; Massanella M; Llibre JM; Ballestero M; Buzon MJ; Ouchi D; Esteve A; Boix J; Manzardo C; Miró JM; Gatell JM; Clotet B; Blanco J; Martinez-Picado J;
AIDS; 2014 Jan; 28(3):325-34. PubMed ID: 24185044
[TBL] [Abstract][Full Text] [Related]
20. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.
Mocroft A; Phillips AN; Ledergerber B; Smith C; Bogner JR; Lacombe K; Wiercinska-Drapalo A; Reiss P; Kirk O; Lundgren JD;
Antivir Ther; 2010; 15(4):563-70. PubMed ID: 20587849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
